Genetic Discovery May Help Determine Effectiveness of Huntington’s Disease Treatments
News Mar 09, 2015
Huntington’s Disease is a fatal, inherited neurological disease that usually manifests between 30 and 50 years of age. The disease is caused by a genetic defect that is passed from parent to child in the huntingtin gene. Having too many repeated elements in the gene sequence causes the disease and an increasing number of repeats leads to earlier onset and increased severity of the disease.
Great efforts have been recently invested in research of biomarkers that would accurately determine the severity of Huntington’s disease even before the onset of symptoms. A study by BUSM researchers, published in BMC Medical Genomics, may provide insight for treatments that would be effective in slowing down or postponing the death of neurons for people who carry the HD gene mutation, but who do not yet show symptoms of the disease.
They studied the brains of people who died from HD and those who died of other, non-neurological diseases and identified a very specific genetic signal that strongly correlates disease severity and extent of neuronal or brain cell death. This genetic signal, also called a miR-10b-5p microRNA, silences certain genes that lead to the toxic effects of the huntingtin gene.
“The findings that we found most interesting were the microRNAs that reflect the extent of the neuron death in the brain, since it is this process that causes the debilitating symptoms of the disease and eventually leads to the death of the individual,” explained senior author Richard H. Myers, PhD, Director of the Genome Science Institute at BUSM.
According to the researchers these findings may represent a more effective way to tell whether or not HD treatments may be slowing down the pace of the death of brain cells. “If miR-10b-5p measurements can provide a faster and more effective way to determine whether or not a specific treatment is protecting brain neurons, it may be possible to study more potential treatments for HD more quickly. Equally importantly, it may become feasible to perform these trials in people who are HD gene carriers, but who do not yet show symptoms, by giving evidence for which trials may postpone onset and provide more healthy years of life,” added Myers.
These findings also suggest that other microRNAs may also be important markers of severity for other neurological diseases such as Parkinson’s disease and Alzheimer’s disease. Further research is already being conducted in Parkinson’s Disease by Myers and his colleagues.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE